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Summary.-The responses of four murine lymphomata, transplanted in their
syngeneic hosts and differing widely in their biological properties such as tendency
to metastasize and " strength " of tumour specific antigen, to immunotherapy, were
investigated. Following the injection of a known number of tumour cells, the mice
were treated either by administration of irradiated tumour cells, living BCG or both.
In general, the response to BCG alone was small even inthemostresponsivetumours,
irradiated cells were more effective and the best results were obtained by a combina-
tion of the two procedures. " Cures " were only obtained with the most antigenic of
the tumours tested and then only when the live tumour cells were inoculated intra-
peritoneally. Theeffectofthese treatments on the rate of growthoftumour whenthe
cells were given subcutaneously was small but the rate at which metastatic spread
occurred from the s.c. site was slowed and for one of these tumours this was quite
marked.
PROTECTION of animals against a
syngeneic tumour graft by prior immuni-
zation with cells from the same tumour,
that have been rendered incapable of
growth by exposure to x-rays, constitutes
evidence for the presence of tumour
specific antigen of the transplantation
type. The growth of some syngeneic
tumours is retarded or prevented in
animals that have, prior to graft, received
treatments that stimulated the reticulo-
endothelial system, such as the adminis-
tration of Bacillus Calmett-Guerin (BCG)
(Old et al., 1961; Weiss, Bonhag and De
Orme, 1961), or Corynebacterium parvum
(Woodruff and Boak, 1966).
The administration of BCG or C.
parvum, besides protecting prophylactic-
ally, will slow the growth of some estab-
lished tumours (Mathe, Pouillart and
Lapeyraque, 1969; Woodruff and Boak,
1966). A very striking effect (Currie and
Bagshaw, 1970) was obtained by admin-
istering C. parvum after the tumour size
had been reduced by chemotherapy.
With the L1210 murine lymphoma Mathe
observed that a combination ofBCG with
irradiated tumour cells was more effective
than either treatment alone.
Haddow and Alexander (1964) found in
rats that injection ofirradiated autologous
tumour cells (obtained by biopsy from
autochthonous chemically induced sar-
coma) slowed the growth of the primary
tumour but only ifthe amount of tumour
present was small. This observation
was also made by Mathe (Mathe, 1968;
Mathe et al., 1969) who treated mice
carrying a subcutaneous graft of L1210
tumour cells with irradiated syngeneic
tumour cells. A possible mechanism was
suggested bythefinding inrats (Alexander
et at., 1969) that the function of the node
draining the primary tumour is impaired,
and that by stimulating uninvolved nodes
with irradiated tumour cells the cell-
mediated host response was increased.
In this paper we report experiments to
study the effect of giving irradiated cells,
BCG and the two procedures combined,
on the growth in syngeneic hosts of 4
murine lymphomata which differ widelyRESPONSE OF SYNGENEIC MURINE LYMPHOMATA
TABLE I.-Summary ofProperties of Murine Lymphomata Described in Test
Mouse of Capacity: to
our* origin Method of induction (date) Immunogenicityt metastasize
Methylcholanthrene 1961 . +
From L5178Y 1968 . +
Methylcholanthrene 1968 . +
Whole-body x-irradiation 1967 . +
+~~~
* In the case of all 4 tumours injection of 10 i.p. cells gave 100% mortality.
t Measured in terms of immunization against an i.p. live cell challenge.
I From a s.c. site of implant.
in their biological properties, such as the
strength of their tumour specific antigens
and their capacity to metastasize.
METHODS
The mice were reared under specific
pathogen-free conditions, kept caged in
groups of5 and fed food and water ad libitum.
The murine lymphomata used in these
studies (Table I) were induced chemically or
by x-irradiation and have been adapted to
grow as ascitic tumours in the peritoneal
cavity. They were maintained by weekly
serial passage of washed, counted tumour
cells. At 4-5 monthly intervals the tumours
were re-established from stock cells from a
tumour bank maintained in liquid nitrogen.
Tumour cell suspensions were irradiated
with 250 kpV x-rays. To ensure that the
cells were oxygenated the cell suspensions
0
were diluted to 2 x 106 cells/ml, or in some
cases 107 cells/ml, with ice-cold TC 199
medium just before irradiation. A dose of
3000 rad given under these conditions was
sufficient to stop an inoculum of 108 cells
from growing when injected. Dried BCG
vaccine (in the form for percutaneous in-
jection) was kindly supplied by Glaxo.
Assay of immunogenicity of tumours.-
Mice were immunized intraperitoneally (i.p.)
with measured doses of irradiated syngeneic
tumour cells and subsequently challenged 7
days later with serial dilutions of viable
tumour cells. The degree of tumour
immunity achieved was measured in terms of
the number of mice free of tumour 6 weeks
after tumour challenge.
Assessment of metastasizing properties of
the tumours.-This was made in terms of the
survival time of mice given subcutaneous
(s.c.) implants of tumour. Cells metasta-
sized mainly to the liver and spleen.
DAYS AFTER TRANSPLANT
Fio. 1.-Mortality curves for the 4 lymphomata when 105 cells are injected s.c. Ten animals per
group. I, TLC5; II, L5178Y-M; III, TLX9; IV, L5178Y-(s.c.); V, L5178Y-(i.d.).
Tumr
L5178Y
L5178Y-M
TLC5
TLX9
--DA ---
DBA/2
DBA/2
CBA
C57B1
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RESULTS
1. Properties of the tumours
Table I gives brief details of the 4
lymphomata used in this study, viz.
method and date of induction, immuno-
genicity and capacity to metastasize.
The experimental basis for the summary
is given in Tables II and III. With regard
to capacity to metastasize from the site
of the primary inoculum the lymphomata
vary greatly (Fig. 1). Mice carrying
TLC5 or L5178Y-M as a subcutaneous
graft die with widespread metastases to
liver and spleen when the primary tumour
massis3-4 mmindiameter, while L5178Y-
original line tumour cells will grow to
form a substantial subcutaneous tumour
approximately 20 x 20 mm in 4-5 weeks.
At this time there is microscopic infiltra-
tion of the liver in some of the animals
but in others the liver and spleen are only
slightly heavier than normal values.
Intradermal transplants of L5178Y meta-
stasize rather less frequently from the
primary site; the few deaths recorded
(Fig. 1) during the 5-6 weeks the animals
were kept alive were the result oftumours
invading the body wall and entering the
body cavity.
An increased facility to form metastases
is paralleled by a decisive fall in immuno-
genicity (Table I). This is particularly
markedinthe case ofthe 2linesofL5178Y,
where one is immunogenic and non-meta-
stasizing,L5178Y,whiletheother L5178Y-
M is metastasizing and but weakly
immunogenic.
Tables II and III give details of the
antigenic properties of the four lympho-
mata studied. Although in general
the L5178Y tumour possessed by far the
strongest tumour specific antigens the
actual level of immunogenicity recorded
for this lymphoma was dependent upon
the site ofinjection ofthe live tumour cell
challenge, e.g. intraperitoneal or subcuta-
neous. Thus DBA/2 mice rendered
immune to an intraperitoneal challenge
of 106 L5178Y cells were not protected
against the same dose of cells given s.c.
Immunotherapy techniques were therefore
investigated on both intraperitoneal and
subcutaneously growing tumours. In the
case of the less immunogenic tumours,
e.g. TLC5, the degree of protection
afforded by immunization was much less
for both s.c. and i.p. challenges and here
the differences between the two sites were
not so apparent.
TABLE II.-Immunogenicity of 4 Murine Lymphomata Measured Against an
Intraperitoneal Challenge
No. of
immuni-
Tumour zations*
L5178Y 1
L5178Y-M . 1
TLC5 . 1
TLX9 . 1
L5178Y . 2
3
L5178Y-M . 2
TLC5 . 2
TLX9 . 2
3
No. of irradiated
cells/immunization
5 x 106
10 X 106
25 x 106
1O0 X 106
5x 106; 5 x 106
5 x 106; 5x 106;
5 x 106
lox 106; lox 106
lOx 106; 20x 106
10x 106; 20 x 106
lOx 106; 20x 106
20x 106
Route of
immuni-
zation
i.p.
multi-sitet
multi-site
multi-site
i.p.
multi-site
multi-site
multi-site
multi-site
Titration with grade cell dosest
Survivors
Total no. injected with tumour cells
t K
102
10/10
4/5
4/10
0/10
3/5
N.T.
3/10
8/10
103
10/10
1/5
1/10
105
10/10
0/5
106 107
9/10 0/10
106
10/10 6/10
10/10 10/10 6/10
3/5
10/10
2/10
3/10
0/5
8/10
N.T.
0/10
10/10 N.T
*Separated by 7 days.
t Given 7 days after last immunization.
$ Irradiated cells divided equally between 4 s.c. sites and i.p.-1/5 total cells/site.
N.B.: For all the tumours listed 10 cells i.p. gave 100% mortality.
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TABLE III.-Immunogenicity of 2 Murine Lymphomata Measured Against a
Subcutaneous Challenge
No. of
Tumour immunizations
L5178Y . 1
1
2
3
TLC5
No. of irradiated
cells/immunization
5x 106
40 x 106
5x 106; 5x 106
5x 106; 5 X 106
5x 106
1 . 25 x 106
2 . 10 x 106; 25 x 106
Route of
immunization
i.p.
multi-site
i.p.
i.p.
multi-site
multi-site
Titration with graded cell doses
Survivors*
Total no. injected with
tumour cells s.c.
104 105 lo6 107
2/5 1/5 0/5 NT
3/5 2/5
5/5 4/5 2/5 1/5
NT 5/5 4/5 3/5
2/5 0/5
5/5 3/5 0/5
* Animals free of tumour 60 days after implant.
N.B.: For L5178Y 105 cells s.c. gave 100% mortality; for TLC5 102 cells s.c. gave 100% mortality.
2. Effect of immunotherapy on the growth
of intraperitoneal tumour
L5178Y lymphoma - non - metastasizing
line.-Sixty mice (DBA/2) received 103
L5178Y lymphoma cells i.p. and were then
10 LIVE TUMOUR CELLS l.P
IRRADIATED CELLS
+BCG.
BCG .
S
IRRADIATED CELLS GIVEN
72 HOURS AFTER TUMOUR.
IRRADIATED CELLS GIVEN
24 HOURS AFrERTUMOUR
FiG. 2.tImmunotherapy of L5178Y lymphoma
growing i.p. 103 L5178Y cells injected i.p. on
day 0. All treatments (except for one group)
given 24 hours after tumour cells. 0, Death of
mouse; 0 -+. survivors free of tumour.
divided into 4 groups. The first was the
control group and received no further
treatment. The second was injected i.p.
with 40-50 x 106 irradiated tumour cells
24 hours after the live lymphoma cells.
The third group received one i.p. injection
of BCG (equivalent to 0-6 mg w/w of
bacteria) 24 hours after tumour challenge,
while the final group was injected i.p.
with both irradiated tumour cells and
BCG (given 3 hours after the irradiated
cells) 24 hours after tumour challenge.
BCG alone had little effect on the rate
at which this tumour killed the animals.
103 L5178Y CELLS
.CI A C
.BCG b IRRADIATED CELLS
MIXED BEFORE
INJECTION
BCG & IRRADIATED CELLS 0.
GIVEN SEPARATELY
BCG
IRRADIATED CELLS C-
CONTROLS
15 20 30 5O
TIME IN DAYS AFTER TRANSPLANT
FIG. 3.-Immunotherapy of L5178Y growing i.p.
Effect of mixing BCG and irradiated cells to-
gether before injection. Treatments given 24
hours after tumour cells. 0, Death of mouse;
0, survivors free of tumour.
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Irradiated tumour cells alone had a
decisive therapeutic effect and administra-
tion of both BCG and irradiated cells
protected 66 % ofthe mice (Fig. 2). When
immunotherapy was delayed until 3 days
after tumour transplant, very little protec-
tionwas affordedtothe mice (Fig. 2); when
the intervalwas 7 days the treated animals
died at the same time as the controls. If
BOG and irradiated cells were mixed
together prior to injection, the protective
effects of both treatments were cancelled
(Fig. 3).
The controls died with ascites and
widespread tumour masses in the peri-
toneal cavity. There was little tumour
spread to the liver or spleen. Those
treated animals which died at the same
time as the controls presented a similar
picture at post-mortem; whereas those
animals which died 10-20 days after the
controls did not have ascites and few
animals had tumour masses in the peri-
toneal cavity. The main post-mortem
feature in these animals was an enlarged
liver and in some cases an enlarged spleen,
which on histological examination proved
to be widely infiltrated with lymphoma
cells.
Various alterations in the experimental
routine such as increase in the number
of irradiated cells (up to 100 x 106),
repeated doses of irradiated cells and
changes in route of administration, did
not appear to have much effect on the
number of " cures " obtained (Table IV).
TABLEIV.-Immunotherapywithlrradiated
Cells against i.p. Tumour. Effect of
Changing Numbers of Cells Given and
Route of Injection
Immunotherapy
Route of No. of irradiated
injection cells
i.p. 40 x 106
i.p. 100 X 106
s.c. 40 x 106
i.p. 40 x 106 (repeated
x 2 per week)
None (controls)
Survivors*
Total no. of
animals im-
planted with 103
i.p. L5178Y cells
2/5
2/5
2/5
2/5
0/5
* Mice free of tumour 60 days after implant.
Survivors of the experiment just
described were killed 4-6 months after
102 TLCS CELLS I.P. 102 TLX9 CELLS l.P.
IRRADIATED CELLS .A
BCG 4 HOURS
AFTER TUMOUR
BCG 4 HOURS
AFTER TUMOUR S
IRRADIATED CELLS :
4 HOURS
AFTER TUMOUR
CONTROLS
I.-
0 10 20 "/5SO
(a)
IRRADIATED CELLS
& BCG 24 HOURS
AFTER TUMOUR
BCG 24 HOURS
AFTER TUMOUR
IRRADIATED CELLS
24 HOURS
AFTER TUMOUR
CONTROLS
0 10 20 so
TIME IN DAYS AFTER TRANSPLANT
(b)
IRRADIATED CELLS
& 8CG 24 HOURS
AFTER TUMOUR
i
IRRADIATED CELLS
24 HOURS
AFTER TUMOUR
CONTROLS
I * I
II--
) 10 20 50
(c)
FIG. 4.-(a) Immunotherapy of TLC5 lymphoma growing i.p. 102 TLC5 lymphoma cells were
injected i.p. day 0. Treatment given 4 hours after tumour cells. (b) Immunotherapy of TLX9
lymphoma growing i.p. 102 TLX9 cells injected i.p. on day 0. Treatment given 24 hours after
tumour cells. (c) Immunotherapy of L5178Y-M growing i.p. Treatment given 24 hours after
tumour cells (103) i.p. 0, Death of mouse; 0-, survivors free of tumour.
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tumour challenge and tissues (liver, spleen
and lymph nodes) were taken from a
representative number and examined his-
tologically for tumour cell infiltration.
None was found.
L5178Y-M lymphonma.-The experi-
ments followed a similar pattern to those
described in the previous section except
that groups treated with BCG only were
omitted. Fig. 4 illustrates the complete
lack ofresponse ofthis tumourto immuno-
therapy.
TLC5 and TLX9 lymphomata.-Again
the design ofexperimentswas the same as
that described for the L5178Y line, except
that the aliquots of irradiated cells
were injected at 4 s.c. sites and i.p. 2-4
hours after the live tumour cell challenge
in the case of TLC5. Slight prolongation
oflife was observed in some ofthe treated
mice but in terms of surviving animals,
immunotherapy had virtually no effect.
3. Effect of immunotherapy on the growth
ofsubcutaneous tumour
L5178Y lymphoma.-In preliminary
experiments using small tumour cell
inocula of 103 and 104, immunotherapy,
if it had any effect at all, appeared to
accelerate the rate of growth of the s.c.
tumours. However, using this route of
injection 100 % "take" of the tumour
graft was not achieved with inocula less
than 105. For the main series of experi-
ments 40 mice were injected s.c. in the
flank with 105 cells (in 0-1 vol.), then
divided into 4 groups. Ten controls
received no further treatment. Twenty-
four hours later 10 mice were injected i.p.
with 40 x 106 irradiated cells, a further
10 received BCG, and the final group was
given irradiated cells 40 x 106 and BCG
with a 3-4 hour interval between the 2
treatments.
The rate of growth of the primary
tumour was not changed by any of these
treatments. On post-mortem examina-
tion of the animals (5 weeks after tumour
cell implant) macroscopic infiltration of
the liver was present in more oftheanimals
in the control and BCG-treated groups
than in the other 2 groups (Table V).
TABLE V.-CoMparison of the Number of
Animals with Liver Metastases 5 Weeks
after 105 L5178Y Lymphoma Cells
Transplanted s.c. and Followed by
"Immunotherapy "
No. of animals with
macroscopic liver
infiltration
Total no. of mice
injected with
Type of treatment 105 s.c.
None . 6/10
* BCG 24 hours after tumour . 8/10
* Irradiated cells 40 x 106 . 3/10
24 hours after tumour
*Irradiated cells 40 x 10and.
BCG 24 hours after tumour
* Given i.p.
2/10
L5178Y-M lymphoma.-Experiments
ofsimilar design to those described for the
original line of L5178Y failed to demon-
strate any effect whatsoever on the rate of
growth of the s.c. tumour. The animals
didnot survive long enoughforthe tumour
to ulcerate but died approximately 21
days after transplant of 104 cells, with
widespread metastases in the liver and
spleen.
TLX9.-Here again, although quite
sizeable tumours were formed, the treat-
ment had no effect either on the size ofthe
tumour or on the times of survival.
TLC5.-An inoculum of 104 tumour
cells was given s.c. to 80 animals which
were divided into 4 groups of 20 animals
each. One group had no further treat-
ment, one group received irradiated cells
(40 x 106/mouse), one group received
BCG, and the final group both irradiated
cells (40 x 106/mouse) and BCG. Treat-
ment was given 4 hours after tumour cells.
All 20 ofthe control animals died between
12 and 15 days. Similarly, BCG-treated
animals died between day 12 and day 14
after tumour cell implant. Animals in
these groups had very small subcutaneous
tumours but there were widespread meta-
stases in theliver, spleen andlymph nodes.
In those mice given irradiated cells or
irradiated cells plus BCG, longer periods of
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20
104 TLCS CELLS S.C
3CG 4 HOURS'
AFTER TUMOUR
IRRADIATED CELLS
& BCG 4 HOURS .
AFTER TUMOUR _
IRRADIATED CELLS
4 HOURS v
AFTER TUMOUR
CONTROLS
IC- CELLS S C.
I~~~~~~~~
10 20 30 40
TIME IN DAYS AFTER TRANSPLANT
FIG. 5. Immunotherapy of TLC5 lymphoma grow-
ing s.c. 104 TLC5 cells injected s.c. on day 0.
Treatment given 2 hours later. 0, Death of
mouse.
survival were found (Fig. 5). Thus,
although in effect the tumours in the
treated animals grew to a larger size than
in the control and BCG groups (Fig. 6),
this was a direct result of longer survival
periods. These treatments, as in the case
of the L5178Y, had no effect on size of
subcutaneous tumour but reduced the
number of metastases.
4. The effect of immunotherapy on the
growth of intradermal tumour
L5178Y lymphoma.-A group of 40
animals was treated in the same manner
as in the experiments described in the
previous section except that the tumour
cells were injected intradermally. The
rate of tumour growth was slowed in the
group given BCG. All the animals were
killed 4-5 weeks after implantation
because of bad ulceration in some of the
tumours. Although the average tumour
weight ofthe group treated with BCG was
smaller than that ofthe control group, this
difference was not statistically significant.
Tumour cell infiltration of the liver was
macroscopically observed in 2 of the
controls only.
a 15
0
D
UJ
cr
H10
Lii
0
cr
Ui
> 5
10 20 30
DAYS AFTER TRANSPLANT
FIG. 6.-Failure of immunotherapy to influence
growth of primary inoculum. Rate of growth of
TLC5 lymphoma injected s.c. (104). ...... Con-
trol, -. - - - BCG, both graphs ceased day 12
because all animals died days 12-14-cf. Fig. 5.
Irradiated cells (40 x 106) and BCG
--.---Irradiated cells (40 x 106).
DISCUSSION
It appears that the primary immune
response induced by a tumour graft of
L5178Y cells given by the i.p. route is
either not strong enough or is not mounted
in time to overcome the progressively
increasing numbers of ascitic cells. As
few as 10 cells can kill 26-28 days after
implant. Further stimulation of the
immune mechanism by active immuno-
therapy, specific (irradiated cells) or non-
specific (BCG) or a combination of the
2, given 24 hours after live tumour cells
greatly increased the average survival
time of mice carrying an i.p. tumour, and
in certain instances " cures " were
achieved. Under these experimental con-
ditions, i.e. when the tumour cell challenge
with L5178Y is i.p., addition of BCG
increased the efficiency of specific immu-
notherapy (Fig. 2). Immunotherapy was
effective only when the tumour cell
180
I
I
I
f
5RESPONSE OF SYNGENEIC MURINE LYMPHOMATA
burden was small-treatment delayed
until 3 days after live tumour implant
was not successful. The irradiated cells
were given i.p. in most experiments but
were just as effective by the subcutaneous
route. Thus, the inflammatory type of
stimulation which could result from the
injection of 40 x 106 irradiated cells into
the peritoneal cavity is not essential for
the curative effects ofthis treatment to be
manifest.
The apparentfailure ofimmunotherapy
to protect fully against an i.p. implant of
the metastasizing TLC5 lymphoma could
be explained in terms of the lower anti-
genicity of this tumour (2 immunizations
are necessary to protect against a chal-
lenge of 106 cells i.p.). Although in terms
of survivors the experiments with TLC5
and TLX9 were failures the small degree
ofprotection afforded by specific immuno-
therapy might encourage the use of these
tumours or ones of similar type as models
on which might be tested and developed
new and better immunotherapy tech-
niques.
Immunotherapy had no effect on the
rate ofgrowth ofany ofthe 4 lymphomata
when the cells were grafted in a s.c. site,
but it reduced the rate of tumour meta-
stases to the liver. This effect was
detected in the series of experiments with
L5178Y but was more easily demon-
strated in the metastasizing lymphoma
TLC5 where survival times could be taken
as a measure of rate of metastases forma-
tion. In neither series of experiments
did BCG noticeably increase the efficiency
of specific immunotherapy.
The failure of immunotherapy in our
experiments to influence the rate of
growth of s.c. tumours contrasts with
results obtained by Mathe (1968) and
Mathe et al. (1969) where complete regres-
sion of some of the s.c. tumours of L1210
(murine lymphoma) occurred. In other
mice the increase intumoursizewas halted
and held at a plateau level for several
weeks. Possibly in this latter group of
animals a reduction in the number of
metastases to the liver was responsible
for prolongation of life, as in the present
experiments.
Although the rate ofgrowth ofL5178Y
as a s.c. tumour was unaffected by
immunotherapy, when the cells were
placed intradermally, BCG had a small
growth-retarding effect. Intradermally
placed lymphoma cells grow at the same
initial rate, i.e. the tumours attain the
same size as tumours growing in a s.c.
site; but during the second week after
transplant, the rate of growth of the
intradermal tumours is slowed. This
could be the result of an immune reaction
on the part ofthe animal to cells placed in
this position. It was not possible to
increase the specific element further by
treatment with irradiated cells but stimu-
lation of the reticuloendothelial system
with BCG slowed tumour growth.
Comparison of the 4 tumours in terms
ofimmunogenicity and metastasizing pro-
perties showedthatthe onethatresponded
most easily to immunotherapy L5178Y,
was the least metastasizing and the most
immunogenic. The loss of immuno-
genicity that occurred as the M line of
L5178Y evolved was accompanied by an
increased ability to metastasize from both
i.p. and s.c. sites and total failure to
respond to the type of immunotherapy
applied. On the other hand, TLC5 which
metastasizes just as rapidly from a s.c.
site can be influenced by immunotherapy.
It is perhaps significant that the immuno-
genicity ofthis tumour (measured in terms
of resistance of immunized animals to
graded challenge dose inocula) is greater
than that of L5178Y-M line. The lym-
phoma TLX9 which metastasizes but not
quite so readily as TLC5 and L5178Y-M
responded but slightly to immunotherapy
and then only when the live cells were
given i.p. The antigenicity ofthis tumour
was as low or lower even than that of
L5178Y-M line.
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